TECH vs DBVT vs IQV vs RGEN vs CRL

For growth investors, Repligen Corporation (RGEN) is the stronger pick with 16.

4% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Bio-Techne Corporation (TECH) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 8x versus Repligen Corporation at 147. 0x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x.

Over the past 5 years, IQVIA Holdings Inc.

(IQV) delivered a total return of -23. 8%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: RGEN returned +369. 1% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DBV Technologies S.

A. (DBVT) is the lower-risk stock at 1. 26β versus Repligen Corporation's 1. 76β — meaning RGEN is approximately 40% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Repligen Corporation (RGEN) is pulling ahead at 16.

4% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — TECH leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 1x forward P/E versus 64. 3x for Repligen Corporation — 50. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, TECH (0.

6% yield) pays a dividend. DBVT, IQV, RGEN, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bio-Techne Corporation (TECH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0.

6% yield, +112. 5% 10Y return). Repligen Corporation (RGEN) carries a higher beta of 1. 76 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TECH: +112. 5%, RGEN: +369. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TECH is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; IQV is a mid-cap quality compounder stock; RGEN is a small-cap high-growth stock; CRL is a small-cap quality compounder stock. TECH pays a dividend while DBVT, IQV, RGEN, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.